2019 Fiscal Year Final Research Report
Development of retrotransposon gene PEG10 targeting treatment for neuroendocrine prostate cancer
| Project/Area Number |
17K11133
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
山崎 俊成 京都大学, 医学研究科, 講師 (00607749)
井上 貴博 京都大学, 医学研究科, 准教授 (80511881)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Keywords | 神経内分泌前立腺癌 / PEG10 / PDX / 細胞株 |
|---|
| Outline of Final Research Achievements |
PEG10 is a unique particle derived from retrotransposon and promotes growth and invasion of neuroendocrine prostate cancer (NEPC). At first, we aimed to elucidate the mechanism of tumor proliferation focused on the particle interacting with PEG10, but enough achievements were not obtained. Next, we tried to culture xenograft model and cell line derived from a NEPC patient. We succeeded in establishing a new NEPC model named KUCaP13. We confirmed that the model was derived from prostate cancer and that it had features of NEPC. Furthermore, we generated the PEG10 knockdown (shPEG10) strain and evaluated its proliferation in vivo. The growth of shPEG10 was suppressed clearly, and this result suggested that PEG10 could be a therapeutic target.
|
| Free Research Field |
泌尿器科癌
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究ではPEG10を標的とした具体的な治療法開発までは到達できなかったが、NEPC患者由来の新規実験モデルが樹立できた。前立腺癌治療中に発生したNEPCであり、近年AR標的薬の増加に伴い増えているNEPCを反映する非常に有用な実験モデルである。このような特徴を有する細胞株の樹立は今までになく、KUCaP13は治療探索において貴重な細胞株と言える。
今回作成されたKUCaP13のNEPC細胞株を使って改めてPEG10が治療標的となりうると確認できたことは大きな前進であり、今後この細胞株を利用した様々な実験系が想定され、新規治療開発への手掛かりとなることが期待される。
|
